Graeme Doran

Graeme is a molecular biologist who led the development of microbial sequencing technologies as CSO of Pathogenica, and commercialized multiplexed biomarker product lines as a Director at Firefly BioWorks, which was acquired by Abcam in 2015. Graeme’s postdoctoral training at MIT and Harvard Medical School focused on non-coding RNA biology, and he holds an MBiochem in Biochemistry and DPhil in Human Genetics from Oxford University.